IFM Therapeutics, LLC logo

IFM Therapeutics, LLC

Transforming treatment for inflammatory disease and cancer by developing drugs that target the innate immune system, the bodys first line of response IFM Therapeutics, Inc., a biopharmaceutical company, develops a portfolio of small molecules that modulate novel targets in the innate immune system as next generation therapies for cancer, autoimmunity, and inflammatory disorders.

IFM Therapeutics, LLC was formed in 2017 following the acquisition of IFM Therapeutics Inc. by Bristol-Myers Squibb. In Aug 2017, Bristol-Myers Squibb acquired IFMs preclinical STING and NLRP3 agonist oncology programs focus on innate immunity in $300 Mn upfront payment and up to $2.02 billion in further milestone payments. IFM Therapeutics, LLC retained its personnel and facilities, as well as its remaining research programs focused on curbing immune responses that lead to inflammatory diseases and fibrosis.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.ifmthera.com
Founded2017
Disease Focus
Development Stage
STOCK CODENon Listed
Address
855 Boylston Street, 11th Floor,MA 2116
Boston
United States
Email
Contact Number
+1 857-304-0583

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/ifmtherapeutics” connections=”true” suffix=””]

IFM Therapeutics current immuno-oncology targets are the key innate immune sensors AIM2 and NLRP1. AIM2 (Absent in Melanoma 2) is a cytosolic DNA-sensing protein. In response to DNA fragments in the cytosol, AIM2 changes shape, and like NLR proteins, triggers inflammasome activation leading to release of inflammatory cytokines and causing an immune-activating form of cell death. Thus combining an AIM2 agonist with checkpoint inhibitors should improve the effectiveness of immune therapy for difficult-to-treat cancers.

IFM Therapeutics was incubated as part of the Atlas Venture seed program in 2015. In June 2016, IFM Therapeutics raised $27 Mn in series A financing round led by Atlas Venture and Abingworth, with participation from Novartis.